Goldman Sachs raised the firm’s price target on Novo Nordisk (NVO) to DKK 436 from DKK 352 and keeps a Buy rating on the shares. The firm believes investor focus in the first half of 2026 will be the launch for Novo’s Wegovy pill. The weight loss pill should contribute to positive earnings momentum in the near term, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Mixed options sentiment in Novo Nordisk with shares down 2.79%
- NVDA, GOOGL, AMZN: Trump’s Greenland Gambit Rattles Big Tech as EU Weighs Salvo
- ‘Sales and Earnings to Shrink in 2026’ TD Cowen Says of Novo Nordisk Stock (NVO)
- Novo Nordisk: Buy Rating Maintained as Pipeline Strength and Franchise Durability Outweigh 2026 Patent and Competitive Headwinds
- Novartis Stock (NVS) Holds on Upbeat View of Tariff Exposure amid U.S.-EU Tension